Editas Medicine Inc
$
25.39
0.6 (2.42%)
| Volume: | 594,681 | Avg Vol (1m): | 714,431 |
| Market Cap $: | 1.25 Bil | Enterprise Value $: | 907.72 Mil |
| P/E (TTM): | 0.00 | P/B: | 5.70 |
| Earnings Power Value | 0 |
| Net Current Asset Value | 3.79 |
| Tangible Book | 4.45 |
| Projected FCF | 0 |
| Median P/S Value | 55.74 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 6/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt |
Cash-To-Debt range over the past 10 years
Min: 0.5, Med: 9.19, Max: 10000
Current: 10000
| |
| Equity-to-Asset | 0.57 |
Equity-to-Asset range over the past 10 years
Min: -0.56, Med: 0.58, Max: 0.81
Current: 0.57
| |
| Debt-to-EBITDA | -0.29 |
Debt-to-EBITDA range over the past 10 years
Min: -5.74, Med: -0.47, Max: -0.29
Current: -0.29
| |
| Piotroski F-Score | 4 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 2.98 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | 2.62 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 0%
WACC 16.07%
| ||
Profitability & Growth : 3/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -377.11 |
Operating Margin range over the past 10 years
Min: -2167.71, Med: -1239.63, Max: -356.1
Current: -377.11
| |
| Net Margin % | -359.94 |
Net Margin range over the past 10 years
Min: -4499.32, Med: -1241.4, Max: -344.28
Current: -359.94
| |
| ROE % | -46.80 |
ROE range over the past 10 years
Min: -377.64, Med: -70.22, Max: -46.8
Current: -46.8
| |
| ROA % | -27.28 |
ROA range over the past 10 years
Min: -190.8, Med: -51.37, Max: -27.28
Current: -27.28
| |
| ROC (Joel Greenblatt) % | -338.82 |
ROC (Joel Greenblatt) range over the past 10 years
Min: -2186.08, Med: -457.27, Max: -285.48
Current: -338.82
| |
| 3-Year Total Revenue Growth Rate | 169.60 |
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: 145.2
Current: 145.2
| |
| 3-Year Total EBITDA Growth Rate | -46.90 |
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -52.9, Max: -34
Current: -34
|
» EDIT's 30-Y Financials
Financials (Next Earnings Date: 2019-08-06)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:EDIT
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325412   SIC : 2834 |
| Compare | XKRX:095700 NAS:SPPI NYSE:CBM NAS:XLRN NAS:MYOK NAS:AIMT NAS:RXDX BOM:539268 NAS:ESPR NAS:SGMO SZSE:002653 NAS:INSM NAS:ARNA NAS:INVA SZSE:002287 NAS:MDGL NAS:CORT XKRX:005250 NAS:IMGN OSTO:VITR |
| Traded in other countries | 8EM.Germany 0IFK.UK |
| Address | 11 Hurley Street, Cambridge, MA, USA, 02141 |
| Editas Medicine Inc is a US-based genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company operates its business in a single segment of Developing and commercializing genome editing technology. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 5.70 |
PB Ratio range over the past 10 years
Min: 2.74, Med: 5.4, Max: 8.32
Current: 5.7
| |
| PS Ratio | 40.13 |
PS Ratio range over the past 10 years
Min: 26.95, Med: 88.19, Max: 361.16
Current: 40.13
| |
| EV-to-EBIT | -8.01 |
EV-to-EBIT range over the past 10 years
Min: -17.5, Med: -7.55, Max: -2.4
Current: -8.01
| |
| EV-to-EBITDA | -8.17 |
EV-to-EBITDA range over the past 10 years
Min: -17.7, Med: -7.8, Max: -2.5
Current: -8.17
| |
| EV-to-Revenue | 30.17 |
EV-to-Revenue range over the past 10 years
Min: 16.8, Med: 68.4, Max: 280.9
Current: 30.17
| |
| Current Ratio | 8.46 |
Current Ratio range over the past 10 years
Min: 1.74, Med: 11.08, Max: 28.66
Current: 8.46
| |
| Quick Ratio | 8.46 |
Quick Ratio range over the past 10 years
Min: 1.74, Med: 11.08, Max: 28.66
Current: 8.46
| |
| Days Sales Outstanding | 0.36 |
Days Sales Outstanding range over the past 10 years
Min: 0.34, Med: 11.68, Max: 228.32
Current: 0.36
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -9.70 |
3-Year Share Buyback Rate range over the past 10 years
Min: -42.3, Med: -9.7, Max: 0
Current: -9.7
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 5.71 |
Price-to-Tangible-Book range over the past 10 years
Min: 2.82, Med: 5.43, Max: 7.37
Current: 5.71
| |
| Price-to-Median-PS-Value | 0.46 |
Price-to-Median-PS-Value range over the past 10 years
Min: 0.38, Med: 0.96, Max: 3.5
Current: 0.46
| |
| Earnings Yield (Joel Greenblatt) % | -12.52 |
Earnings Yield (Greenblatt) range over the past 10 years
Min: -41.1, Med: -13.2, Max: -5.7
Current: -12.52
|
More Statistics
| Revenue (TTM) (Mil) $ | 30.08 |
| EPS (TTM) $ | -2.26 |
| Beta | 2.39 |
| Volatility % | 58.52 |
| 52-Week Range $ | 17.8 - 36.3 |
| Shares Outstanding (Mil) | 48.76 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 4 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | Y |